Alvotech Raises $152 Million in Dual Share Offerings to Fuel Biosimilar Expansion
Event summary
- Alvotech priced a $85 million public offering of 22.7 million ordinary shares at $3.75 per share, with an option for underwriters to purchase an additional 3.4 million shares.
- Concurrently, Alvotech raised $67 million through a private placement of 17.8 million shares to certain investors in the European Economic Area.
- Total gross proceeds from both offerings could reach $165 million if the underwriters' option is fully exercised.
- Proceeds will fund biosimilar development, working capital, and potential acquisitions or collaborations.
- The offerings are expected to close on June 17, 2026, and June 25, 2026, respectively.
The big picture
Alvotech's $152 million capital raise underscores the intense funding needs in the biosimilars space, where companies must balance R&D investments with commercialization efforts. The dual offerings reflect a strategic move to secure flexible financing amid a competitive biotech landscape, where scale and global partnerships are critical for success. The proceeds will be pivotal in determining whether Alvotech can sustain its growth trajectory and compete with established players in the biosimilar market.
What we're watching
- Execution Risk
- Whether Alvotech can effectively deploy the proceeds to advance its biosimilar pipeline and achieve commercial milestones.
- Market Dynamics
- How the competitive landscape for biosimilars will impact Alvotech's growth and market positioning.
- Strategic Alliances
- The pace at which Alvotech forms new partnerships or acquisitions to expand its global reach and product portfolio.
Related topics